Christina Carone

Download

Biography

Christina Carone
Christina Carone is an associate in Weil’s Corporate Department and is based in Washington, D.C. Christina advises public and private companies and private equity fund clients on diverse administrative and regulatory compliance matters, including health and safety issues related to food, drugs, dietary supplements, cosmetics and medical devices. She also advises clients in the government services industry on government contracting matters involving the Small Business Administration and other governmental programs, as well as in related regulatory considerations.

Prior to joining Weil, Christina was an associate at another international law firm. Christina has experience advising multinational companies on the safety of chemical substances for food-contact applications; drafting legal opinions on the compliance status of food additives and food-contact substances in multiple jurisdictions; developing strategies to help food-contact product manufacturers bring their products to market; conducting regulatory diligence reviews; and preparing regulatory filings on behalf of clients regarding U.S. Food and Drug Administration matters. Her experience includes:

  • FDA and Product Regulatory Due Diligence: Conducts and manages regulatory due diligence for transactions involving medical devices, drugs, cosmetics and food products, identifying compliance risks and other regulatory considerations related to FDA oversight.
  • Government Contracts and Compliance: Advises M&A and private equity deal teams and clients on federal, state and local government contracting considerations, including procurement compliance and potential regulatory liabilities.
  • Transactional Agreements and Risk Allocation: Drafts and revises transactional agreements to address regulatory risk, including representations and warranties relating to FDA regulatory and government contracting matters.
  • Due Diligence Management: Develops tailored due diligence request lists, prepares agendas for expert interviews, and drafts due diligence memoranda addressing complex regulatory considerations for private equity and corporate clients.

Christina has been part of the teams advising:

  • Advent International
    • in its acquisition of Sauer Brands, Inc.
    • in its acquisition of Atwell, LLC
    • in its $400 million acquisition of the aerospace and defense business of Coherent Corp.
    • in Cobham Ultra Group’s $1.55 billion sale of Ultra PCS to Eaton Corporation
  • Arcosa, Inc. in its $180 million acquisition of Ameron Pole Products
  • Astorg Partners
    • in its approximately $282 million take-private acquisition of Hamilton Thorne and simultaneous acquisition of the Assisted Reproductive Technologies (ART) product portfolio of Cook Medical
    • and its portfolio company Hamilton Thorne Ltd in its acquisition of the assisted reproductive technology and cytogenetics business unit of FUJIFILM Irvine Scientific, Inc.
  • Aterian Investment Partners and its portfolio company Vantedge Medical in its acquisition of Hobson & Motzer, Inc.
  • Avista Capital Partners
    • in its acquisition of WellSpring Consumer Healthcare
    • and its portfolio company WellSpring Consumer Healthcare in its acquisition of a portfolio of over-the-counter skin care brands
  • The Barilla Group in its pending acquisition of GOODLES
  • Blackstone in its $300 million investment in DataDirect Networks, Inc.
  • Clayton Dubilier & Rice in the merger of its portfolio company Cynosure with Lutronic Corporation
  • Cobepa S.A. in its acquisition of Eagle Fire and its investment in SAX
  • Cove Hill Partners
    • in its acquisition of Incident IQ, LLC
    • in its acquisition of Swiftly Parent, Inc.
  • Dycom Industries, Inc. in its $275 million acquisition of National Technology Integrators
  • Eli Lilly and Company
    • in its acquisition of a first-in-class small molecule and related assets from a sponsor-backed research consortium
    • in its acquisition of certain assets from Organovo Holdings, Inc.
    • in its acquisition of a manufacturing facility located in Pleasant Prairie, WI
    • in its sale of ImClone Systems LLC to Celltrion, Inc.
  • Fathom Point Capital in its acquisition of Modus Advanced, LLC
  • Greater Sum Ventures
    • in its acquisition of Strax Technologies, LLC
    • in its acquisition of Utility Associates, Inc.
    • and Utility Associates, Inc. in its acquisition of SOMA Global, Inc.
  • Halozyme Therapeutics, Inc.
    • in its $400 million acquisition of Surf Bio, Inc.
    • in its $960 million acquisition of Antares Pharma, Inc.
  • Hologic, Inc in its $350 million acquisition of Gynesonics, Inc.
  • Jack Creek Investment Corp., a SPAC sponsored by KSH Capital, in its business combination with Bridger Aerospace Group Holdings, LLC, in a transaction valuing Bridger at $869 million
  • The Kroger Company, along with The Albertsons Companies, Inc., in the approximately $1.9 billion sale of 413 stores, as well as select banners, distribution centers, offices and private label brands, to C&S Wholesale Grocers, LLC in connection with Kroger’s proposed merger with Albertsons Companies Inc.
  • L’Oréal in its acquisition of Color Wow
  • Montagu Private Equity
    • in its acquisition of Tyber Medical LLC and combination with Intech and Resolve
    • in RTI Surgical, Inc.’s acquisition of Cook Biotech Incorporated and Cook Biotech Europe ApS
  • OMERS in its acquisition of Pueblo Mechanical & Controls
  • One Investment Management in its $200 million investment in Noveon Magnetics Inc.
  • PAI Partners in its acquisition of Alphia Inc.
  • Peak Rock Capital and its portfolio company The Tranzonic Companies in its acquisition of Supply Source Enterprises, Inc.
  • Providence Equity Partners L.L.C. in its acquisition of Modern Campus
  • PSG Equity
    • in its acquisition of Benchmark Solutions, LLC
    • in its acquisition of Glasswall Holdings
    • in its acquisition of ClassTag Inc.
  • Sanofi
    • in its $2.2 billion acquisition of Inhibrx, Inc.
    • in its $2.2 billion acquisition of Dynavax Technologies
    • in its $9.5 billion acquisition of Blueprint Medicines
    • in its $2.9 billion acquisition of Provention Bio Inc.
  • Seven2 and its portfolio company Vitaprotech Group SAS in its acquisition of the physical security, access card, and identity reader operations and assets of Identiv, Inc.
  • Siete Foods in its $1.2 billion sale to PepsiCo

Christina received her LL.M. from Georgetown University Law Center and her J.D., magna cum laude, from Touro Law Center, where she was a student in the Two-Year Accelerated J.D. Program. Christina received her B.S., cum laude, from the University of Florida.

Latest Thinking, Firm News & Announcements

Latest Thinking

View all

Firm News & Announcements

View all